Program
cenerimod
Also written as “Cenerimod”, “Cenerimod 0.5 mg” and “Cenerimod 4 mg”.
Its studies are mostly in Lupus Erythematosus, Systemic · Lupus Nephritis · Renal Insufficiency, led by Viatris.
Furthest: phase 3, since Dec 5, 202214 company-led studies, 5 open or runningNext primary completion: Dec 31, 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatris | 145 open or running | phase 3since Dec 5, 2022 | May 14, 2015 | Dec 31, 2026phase 3 · NCT05672576 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 14, 2015First study: phase 2 study in Lupus Erythematosus, SystemicFirst studyNCT02472795 · 105 enrolled · United States, Belarus, Bulgaria and more
- Jun 17, 2015Phase 1 study in Healthy SubjectsNCT02479204 · 10 enrolled · France
- Sep 13, 2016Phase 1 study in Healthy SubjectsNCT02914223 · 6 enrolled · Netherlands
- Nov 12, 2018Phase 2 study in Lupus Erythematosus, SystemicNCT03742037 · 427 enrolled · United States, Bulgaria, Chile and more
- Aug 8, 2019Phase 1 study in Healthy VolunteersNCT04052360 · 20 enrolled · United States
- Jan 29, 2020Phase 1 study in Healthy SubjectsNCT04255277 · 97 enrolled · France
- Mar 16, 2021Phase 1 study in HealthyNCT04819464 · 24 enrolled · Hungary, Portugal
- Aug 3, 2021Phase 1 study in Renal InsufficiencyNCT05004311 · 16 enrolled · Portugal
- Dec 5, 2022Phase 3 study in Lupus Erythematosus, SystemicNCT05648500 · 470 enrolled · United States, Argentina, Brazil and more
- Jan 3, 2023Phase 3 study in Lupus Erythematosus, SystemicNCT05672576 · 451 enrolled · United States, Chile, Czechia and more
- Jun 20, 2024Phase 3 study in Lupus Erythematosus, SystemicNCT06475742 · 680 planned · United States, Argentina, Brazil and more
- Sep 23, 2025Phase 3 study in Lupus NephritisNCT07201129 · 300 planned · United States
- Nov 17, 2025Phase 1 study in Healthy SubjectsNCT07301723 · 6 enrolled · Netherlands
- Nov 17, 2025Phase 2 study in Lupus Erythematosus, SystemicNCT07266090 · 15 enrolled · China
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Lupus Erythematosus, SystemicNCT05672576
- Mar 31, 2027Primary completion: phase 3 study in Lupus Erythematosus, SystemicNCT05648500
- Oct 8, 2027Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07266090
- Aug 2029Primary completion: phase 3 study in Lupus NephritisNCT07201129
TargetBeta
S1PR1 →read by rule
“Sphingosine 1-phosphate receptor Edg-1 modulator”ChEMBL 37, by rule
Other programs on S1PR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| fingolimodrule | Novartis | phase 4 | 55 |
| etrasimodrule | Pfizer | phase 3 | 21 |
| ponesimodrule | Johnson & Johnson | phase 3 | 16 |
| mocravimodrule | Novartis | phase 3 | 5 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07301723Healthy Subjects · Netherlands | 1 | Completed | Mar 18, 2026 | 6 |
| NCT07266090Lupus Erythematosus, Systemic · China | 2 | Active, not recruiting | Oct 8, 2027 | 15 |
| NCT07201129Lupus Nephritis · United States | 3 | Recruiting | Aug 2029 | 300 |
| NCT06475742Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 3 | By invitation | Sep 2032 | 680 |
| NCT05672576Lupus Erythematosus, Systemic · United States, Chile, Czechia and more | 3 | Active, not recruiting | Dec 31, 2026 | 451 |
| NCT05648500Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Mar 31, 2027 | 470 |
| NCT05004311Renal Insufficiency · Portugal | 1 | Completed | Jul 27, 2023 | 16 |
| NCT04819464Healthy · Hungary, Portugal | 1 | Completed | Aug 18, 2024 | 24 |
| NCT04255277Healthy Subjects · France | 1 | Completed | Sep 14, 2021 | 97 |
| NCT04052360Healthy Volunteers · United States | 1 | Completed | Oct 29, 2019 | 20 |
| NCT03742037Lupus Erythematosus, Systemic · United States, Bulgaria, Chile and more | 2 | Completed | Aug 31, 2021 | 427 |
| NCT02914223Healthy Subjects · Netherlands | 1 | Completed | Dec 1, 2016 | 6 |
| NCT02479204Healthy Subjects · France | 1 | Terminated | May 1, 2016 | 10 |
| NCT02472795Lupus Erythematosus, Systemic · United States, Belarus, Bulgaria and more | 2 | Completed | Jan 23, 2017 | 105 |
How it is read
Names in the registry
- “Cenerimod”, 9 entries
- “Cenerimod 0.5 mg”, 2 entries
- “Cenerimod 4 mg”, 2 entries
- “Cenerimod 1 mg”, 1 entry
- “Cenerimod 2 mg”, 1 entry
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 6 studies
- Lupus Nephritis, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.